@reiver

Sphingolipids and Axonal Growth

[...] Inhibition of sphingolipid synthesis and degradation have opposite effects on neuronal development. Inhibition of sphingolipid synthesis by fumonisin B1 or D-PDMP results in a decrease in the rate of axonal growth and a reduction in the number of axonal branch points. In contrast, accumulation of GlcCer by incubation with conduritol-B-epoxide stimulates axonal growth. The figure show camera lucid drawings of representative neurons on day 3 in culture, after addition of the inhibitors on day 0. See text and references (17–19,38,39) for more details. The bar in the box of the control neuron corresponds to 100 ␮m, and examples are given for the control neuron showing the various morphological features of hippocampal neurons. 3-ketoSa, 3-ketosphinganine; Sa, sphinganine; Dihydro-Cer, dihydroceramide; Cer, ceramide; GlcCer, glucosylceramide; GSLs, glycosphingolipids.

[...]

17. Futerman, A. H., Boldin, S., Brann, A. B., Schwarz, A., and Zisling, R. 1998. Regulatory roles for sphingolipids in the growth of polarized neurons. Ann. N. Y. Acad. Sci. 845:176–187.

18. Futerman, A. H. 1998. Distinct roles for sphingolipids and glycosphingolipids at different stages of neuronal development. Acta Biochim. Pol. 45:469–478.

19. Futerman, A. H., Boldin, S. A., Brann, A. B., Pelled, D., Meivar-Levy, I., and Zisling, R. 1999. Regulation of sphingolipid and glycosphingolipid metabolism during neuronal growth and development. Biochem. Soc. Trans. 27:432–437.

[...]

38. Schwarz, A., Rapaport, E., Hirschberg, K., and Futerman, A. H. 1995. A regulatory role for sphingolipids in neuronal growth. Inhibition of sphingolipid synthesis and degradation have opposite effects on axonal branching. J. Biol. Chem. 270:10990–10998.

39. Schwarz, A. and Futerman, A. H. 1997. Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth. J. Neurosci. 17:2929–2938.

-- Rosaria Buccoliero , Jacques Bodennec , Anthony H. Futerman

from "The Role of Sphingolipids in Neuronal Development: Lessons from Models of Sphingolipid Storage Diseases"

Quoted on Mon Oct 29th, 2012